- Home
- NBIX vs SJM Comparison
NBIX vs SJM Comparison
Compare NBIX & SJM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- SJM
- Stock Information
- Founded
- NBIX 1992
- SJM 1897
- Country
- NBIX United States
- SJM United States
- Employees
- NBIX N/A
- SJM N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- SJM Packaged Foods
- Sector
- NBIX Health Care
- SJM Consumer Staples
- Exchange
- NBIX Nasdaq
- SJM Nasdaq
- Market Cap
- NBIX 12.0B
- SJM 11.7B
- IPO Year
- NBIX 1996
- SJM N/A
- Fundamental
- Price
- NBIX $123.02
- SJM $112.57
- Analyst Decision
- NBIX Strong Buy
- SJM Buy
- Analyst Count
- NBIX 20
- SJM 10
- Target Price
- NBIX $163.20
- SJM $125.70
- AVG Volume (30 Days)
- NBIX 1.6M
- SJM 1.0M
- Earning Date
- NBIX 05-05-2025
- SJM 06-10-2025
- Dividend Yield
- NBIX N/A
- SJM 3.84%
- EPS Growth
- NBIX N/A
- SJM N/A
- EPS
- NBIX 2.96
- SJM N/A
- Revenue
- NBIX $2,412,600,000.00
- SJM $8,788,000,000.00
- Revenue This Year
- NBIX $15.99
- SJM $8.23
- Revenue Next Year
- NBIX $14.93
- SJM $1.86
- P/E Ratio
- NBIX $41.60
- SJM N/A
- Revenue Growth
- NBIX 21.73
- SJM 7.07
- 52 Week Low
- NBIX $84.23
- SJM $98.77
- 52 Week High
- NBIX $157.98
- SJM $125.42
- Technical
- Relative Strength Index (RSI)
- NBIX 62.85
- SJM 48.22
- Support Level
- NBIX $117.59
- SJM $110.29
- Resistance Level
- NBIX $125.63
- SJM $114.11
- Average True Range (ATR)
- NBIX 2.98
- SJM 2.07
- MACD
- NBIX -0.02
- SJM -0.00
- Stochastic Oscillator
- NBIX 72.90
- SJM 51.28
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About SJM The J.M. Smucker Company
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (78% of fiscal 2024 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of Hostess and international (primarily Canada). Retail coffee is its largest category (33% of sales) with brands Folgers and Dunkin'. Pet foods (22% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from consumer foods, primarily peanut butter and jelly, through brands Jif and Smucker's. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.